VIDEO: Study probes treatment of elderly patients with acute myeloid leukemia
In this video, Moath Albliwi, MD, discusses the results of a study he co-presented at ASH Annual Meeting and Exposition that examined treatment of elderly patients with acute myeloid leukemia.
Albliwi, a second-year resident at Cleveland Clinic, highlighted the study, which was a retrospective cohort study into the treatment of patients with newly diagnosed acute myeloid leukemia between the ages of 65 and 75. One arm received 7 days of cytarabine with 3 days of anthracycline (7+3), and the other received venetoclax (Venclexta; AbbVie, Genentech) and a hypomethylating agent.
“There is no significant difference in terms of overall survival, event-free survival and clinical complete response rate. So, this can give us a hint that there is no difference in these two groups,” Albliwi said.
Reference:
- Albliwi M, et al. Abstract 1473. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Collapse
Read more about